Back to Browse Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 1

mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report

Authors Ibeas P, Cantos B, Provencio M.

Published Date November 2011 Volume 2011:1 Pages 19—22

DOI http://dx.doi.org/10.2147/BLCTT.S24910

Published 8 November 2011

Patricia Ibeas, Blanca Cantos, Mariano Provencio
Clinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, Spain

Abstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%–15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.

Keywords: everolimus, positron emission tomography, chemotherapy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

Smaldone MC, Chen DY, Yu JQ, Plimack ER

Biologics: Targets and Therapy 2012, 6:395-407

Published Date: 19 November 2012

Reduced intensity treatment in early-stage Hodgkin’s lymphoma

Prodduturi P, Armitage JO

Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:23-31

Published Date: 25 November 2011

Thermal and ultrasonic influence in the formation of nanometer scale hydroxyapatite bio-ceramic

Poinern GE, Brundavanam RK, Le XT, Djordjevic S, Prokic M, Fawcett D

International Journal of Nanomedicine 2011, 6:2083-2095

Published Date: 23 September 2011

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011